The Power of Renal Function Estimation Equations for Predicting Long-Term Kidney Graft Survival: A Retrospective Comparison of the Chronic Kidney Disease Epidemiology Collaboration and the Modification of Diet in Renal Disease Study Equations by 源�紐낆닔 et al.
icine®
ONAL STUDYMed
OBSERVATIThe Power of Renal Function Estimation Equations for
Predicting Long-Term Kidney Graft Survival
A Retrospective Comparison of the Chronic Kidney Disease Epidemiology
Collaboration and the Modification of Diet in Renal Disease Study EquationsD,Hoon Young Choi, MD, PhD, Dong Jin Joo, MD, Ph
m,
CKD stages classified using the MDRD equation appeared to be in lower
eGFR categories than those classified using the CKD-EPI equation.
Pearson and Spearman correlation analyses indicated that the CKD stage
The first systema
estimation equation i
performed. The autho
Editor: Aleksandra Kukla.
Received: October 30, 2015; revised: January 4, 2016; accepted: January 9,
2016.
From the Department of Internal Medicine, Yonsei University College of
Medicine, Seoul, Korea (HYC, HCP, BSK); Department of Transplantation
Surgery, Severance Hospital, Yonsei University Health System, Seoul,
Korea (DJJ, MSK, YSK); The Research Institute for Transplantation (DJJ,
MSK, YSK, BSK); and Department of Biostatistics Collaboration Unit
(MKS), Yonsei University College of Medicine, Seoul, Korea.
Correspondence: Beom Seok Kim, Department of Internal Medicine,
Yonsei University College of Medicine, Seoul 03722, Korea (e-mail:
docbsk@yuhs.ac).
Yu Seun Kim, Department of Transplantation Surgery, Severance Hospital,
Yonsei University Health System, Seoul 03722, Korea (e-mail:
yukim@yuhs.ac).
This work was financially supported by faculty research grant of Yonsei
University College of Medicine for 2012 (6-2012-0130).
The authors have no conflicts of interest to disclose.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons
Attribution-NonCommercial-NoDerivatives License 4.0, where it is
permissible to download, share and reproduce the work in any medium,
provided it is properly cited. The work cannot be changed in any way or
used commercially.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000002682
Medicine  Volume 95, Number 7, February 2016S, Myoung So
Hyeong Cheon Park, MD, PhD, Yu Seun Ki
Abstract: Evaluation of renal function using an accurate estimation
equation is important for predicting long-term graft survival. We
designed this retrospective cohort study to evaluate the predictive power
of renal function estimation by the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) and the Modification of Diet in Renal
Disease (MDRD) study equations for graft survival.
We reviewed data of 3290 adult kidney transplant recipients who
underwent transplantation at a single center between April 1979 and
September 2012. The reliability and agreement of chronic kidney disease
(CKD) stages based on the estimated glomerular filtration rate (eGFR) as
calculated by the CKD-EPI and MDRD equations were evaluated using
Bland–Altman plots and Cohen weighted kappa analyses. The predictive
power of CKD stages as classified by each equation for graft survival was
investigated using Cox regression models. Additionally, Pearson and
Spearman correlation coefficients were used to reveal the relationship
between graft survival and eGFR equations.
Of 3290 kidney transplant recipients, 3040 were included in the
analysis. The mean follow-up duration was 128.08 83.54 months, and
29.8% of participants were reclassified to higher eGFR categories by the
CKD-EPI equation compared to the category classification by theMDRD
equation. eGFR calculated using the MDRD equation was underesti-
mated compared to that calculated using theCKD-EPI equation, based on
the Bland–Altman plot. In Cohen weighted kappa analysis, agreement
across CKD stages classified using the 2 equations was reliable, but allMi Kyung Song, M o Kim, MD, PhD,
MD, PhD, and Beom Seok Kim, MD, PhD
as classified by the CKD-EPI equation, but not the MDRD equation, was
significantly correlated with the risk of graft failure. In multivariable Cox
regression analysis for graft failure after adjustment for CKD stage as
determined using the MDRD equation, but not the CKD-EPI equation,
stage reclassification was significantly associated with a lower graft
failure risk.
Our data from this long-term follow-up study indicate that the CKD-
EPI equation has a stronger predictive power for kidney graft survival
than does the MDRD equation in transplantation settings.
(Medicine 95(7):e2682)
Abbreviations: AR = acute rejection, BMI = body mass index,
CKD = chronic kidney disease, CKD-EPI = Chronic Kidney
Disease Epidemiology Collaboration, eGFR = estimated
glomerular filtration rate, ESRD = end-stage renal disease, HLA
= human leukocyte antigen, KT = kidney transplantation, MDRD =
Modification of Diet in Renal Disease, mGFR = measured GFR.
INTRODUCTION
C hronic kidney disease (CKD) is a major health problemworldwide, and the number of patients with CKD is rapidly
increasing.1,2 The glomerular filtration rate (GFR) is widely
used to diagnose and evaluate CKD. In particular,
GFR< 60mL/min/1.73m2, considered to indicate impaired
kidney function, has been associated with an increased risk
of progression to kidney failure and is a major risk factor for
negative outcomes associated with CKD. Therefore, an accurate
estimation of GFR is important for detecting CKD and assessing
its severity, predicting kidney survival, and determining the
appropriate management for CKD progression.3–5
Measured GFR (mGFR) is considered the gold standard
marker of renal function in the general population, CKD patients,
and patients who have undergone kidney transplantation (KT), but
its use is limited in routine clinical settings. Estimated GFR (eGFR)
provides an alternative for easily evaluating renal function because
of the simplicity of sampling.6–9 There are several equations for
eGFR that have been applied to evaluate CKD10–13 and these have
beenvalidated inCKDpatients inmany countries and under various
conditions.14–18 However, no single equation for GFR estimation is
appropriate for all populations and GFR ranges.19 Although
equations for GFR calculation were developed usingmGFR, which
reflects the renal clearance of exogenous markers, systematic
differences in these mGFR measurement methods could distort
the validation of results when compared with results obtained by
using the renal clearance of inulin as the gold standard.20,21tic review of a creatinine-based GFR
n solid-organ recipients was recently
rs conducted a study of the diagnostic
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equations and concluded that the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) and the Modification
of Diet in Renal Disease (MDRD) study equations showed
better performance than did alternative creatinine-based esti-
mation equations. Thus, eGFR calculated using the CKD-EPI
and MDRD study equations can be used for routine monitoring
of kidney function in solid-organ transplant recipients.22
Although a kidney function end-point would be ideal for
evaluating definite outcomes related to KT or for developing
clinical trials for patients undergoing KT, the use of such an
endpoint is difficult in a clinical setting due to the large numbers
of patients and the long-term follow-up period needed.23
A large meta-analysis demonstrated that the CKD-EPI
equation was more accurate in categorizing the risk of mortality
and progression to end-stage renal disease (ESRD) than was the
MDRD study equation in a population with a broad range of
demographic and clinical characteristics.24 Moreover, for CKD
patients with type 2 diabetes, the stages based on eGFR as
calculated by the CKD-EPI equation were shown to be more
reliable for risk stratification regarding CKD progression than
were those calculated by the MDRD study equation, especially
in earlier-stage CKD.25
Instead of comparing the accuracy of the CKD-EPI
equation with that of other equations for predicting mGFR,6,9
the present study was conducted to validate the eGFR as
calculated by the CKD-EPI equation compared to the eGFR
FIGURE 1. Algorithm used to define the study cohort.as calculated by the MDRD study equation for predicting long-
term renal outcomes in a large number of KT patients in a
single center.
METHODSStudy Population
This retrospective cohort study included all transplant
recipients who underwent KT at the Severance Hospital
2 | www.md-journal.comTransplantation Center. We obtained the medical records of
all adult patients undergoing KT between April 1979 and
December 2012 who survived least 1 year for inclusion in this
study. A total of 3290 transplant recipients were analyzed; 250
were excluded because of death, graft loss, or loss to follow-up
within 1 year. We also performed a subgroup analysis for
participants without an acute rejection (AR) episode (Figure 1).
This study was approved by the Institutional Review Board
of Severance Hospital, Yonsei University College of Medicine,
Seoul, Korea, and the need for informed consent was waived
due to the retrospective nature of the study.
Immunosuppressive Protocol
Before 1984, participants were primarily treated with
immunosuppressive agents such as azathioprine and predniso-
lone. After 1984, a double regimen with cyclosporine A and
prednisolone, or a triple regimen with the addition of azathiopr-
ine or mycophenolic acid was used. Mycophenolic acid was
introduced in 1997 and was used for appropriate recipients as
part of the triple regimen with a calcineurin inhibitor. Since
1998, the calcineurin inhibitor tacrolimus has been used instead
of cyclosporine A. Induction immunosuppression therapy
(antithymocyte globulin, antilymphocyte globulin, and muro-
monab-CD3) was not used; however, induction therapy with an
interleukin-2 receptor antibody (basiliximab) for high-risk reci-
pients was initiated in 1999.
Steroid pulse therapy (methylprednisolone [500mg/d 4
for 5 days]) was considered the first-line therapy for AR. In the
event of an inadequate response, an antilymphocyte antibody,
such as OKT-3, or an antithymocyte antibody was used.
Clinical Variables
Clinical variables included donor and recipient age andsex, body mass index (BMI), dialysis duration before KT,
human leukocyte antigen (HLA) mismatches, AR within 1 year
of KTand during the follow-up period, diabetes mellitus, kidney
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Baseline Characteristics of Participants Overall and Those Without Acute Rejection
Variables All Participants (n¼ 3040) Participants Without AR (n¼ 1966)
Age, y 39.30 10.85 39.82 10.92
Sex (male, n (%)) 1989 (65.43) 1267 (64.45)
Diabetes (yes, n (%)) 816 (26.84) 497 (25.28)
BMI at KT, kg/m2 21.72 3.16 21.81 3.16
Donor age, y 37.37 11.63 37.22 11.52
Dialysis duration prior KT, mo 23.64 35.84 23.94 36.24
HLA-mismatch (yes, n (%)) 2678 (88.68) 1687 (86.29)
Number of HLA-mismatches per patient 2.41 1.29 2.38 1.35
Donor type (n (%))
LRD 1584 (52.11) 1110 (56.46)
LURD 1206 (39.67) 671 (34.13)
Deceased 250 (8.22) 185 (9.41)
AR during 1st year (yes, n (%)) 873 (30.90) —
Number of AR per patient during 1st year 0.43 0.65 —
MDRD eGFR (ml/min/1.73m2) at 1 year post-KT 59.64 17.51 61.99 15.98
CKD-EPI eGFR (ml/min/1.73m2) at 1 year post-KT 66.54 19.85 69.24 18.16
Graft survival, mo 128.08 83.54 130.84 87.16
Data are expressed as meanSD or frequency (percentage).
AR¼ acute rejection, BMI¼ body mass index, CKD-EPI¼Chronic Kidney Disease Epidemiology Collaboration, eGFR¼ estimated glomerular
lant
Medicine  Volume 95, Number 7, February 2016 Predicting Long-Term Kidney Graft Survivalfunction at 1 year after KT, and graft survival. AR was defined
by the need for treatment, with or without biopsy confirmation.
The total number of HLAmismatches was calculated as the sum
of the mismatches in the A, B, and DR loci. Graft loss was
defined as patient death, graft removal, or conversion to
regular dialysis.
GFR Calculation
eGFR values were calculated using the four-variable
MDRD study equation and the CKD-EPI equations.12,26
MDRD eGFR ¼ 175
 ðserum creatinine in mg=dLÞ1:154
 ðageÞ0:203ð0:742 if femaleÞ:
CKD-EPI eGFR ¼ 141 ðminimum of standardized serum
creatinine ½ mg=dLg=k or1Þa  ðmaximum of standardized
serum creatinine ½ mg=dLg=k or1Þ1:209
0:993ageð1:018 if femaleÞð1:159 if blackÞ
where k is 0.7 for women and 0.9 for men, and a is0.329
for women and 0.411 for men.
For both equations, eGFR was calculated in mL/min/1.73
m2, weight in kg, serum creatinine in mg/dL, and age in years.
CKD was classified into 5 stages based on the eGFR category,
according to the Kidney Disease: Improving Global Outcomes
criteria: stage 1, eGFR 90mL/min/1.73m2; stage 2, eGFR of
60 to 89mL/min/1.73m2; stage 3, eGFR of 30 to 59mL/min/
1.73m2; stage 4, eGFR of 15 to 29mL/min/1.73m2; and stage 5,
eGFR< 15mL/min/1.73m2 or dialysis. Stage 3 CKD was
filtration rate, HLA¼ human leukocyte antigen, KT¼ kidney transp
MDRD¼Modification of Diet in Renal Disease.further divided into 2 subgroups: stage 3a, eGFR 45 to
59mL/min/1.73m2 and stage 3b, eGFR 30 to 44mL/min/
1.73m2.27
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Statistical Analysis
The patients’ baseline characteristics at transplantation and
1 year after transplantation are represented as the mean stan-
standard deviation or frequency (percentage). Bland–Altman
plots were used to examine the agreement between eGFR values
calculated by each equation. The frequency distribution of
participants in each category of eGFR as determined by the
2 equations using clinical reference values (90, 60–89, 45–
59, 30–44, 15–29, and 15mL/min/1.73m2) was confirmed
using contingency tables, and the reliability of each category
was analyzed based on Cohen weighted kappa. The association
of ordinal CKD stages and the overall percentage of graft failure
within each category were assessed based on Pearson and
Spearman correlation coefficients. The Kaplan–Meier method
was used to evaluate graft failure according to CKD stage and
the estimated median graft failure time at each CKD stage.
Cumulative event rates for the CKD stages were compared
using the log-rank test. Univariate and multivariable Cox
regression analyses were performed to investigate the effects
of CKD stage on the prediction of graft failure. P values of
<0.05 were considered statistically significant, and all analyses
were conducted using SAS version 9.2 (SAS Institute, Cary,
NC) and R package version 2.14.2.
RESULTS
A total of 3040 recipients were included in this study
(Figure 1). The baseline characteristics for all participants and
for those without acute rejection (AR) are shown in Table 1. The
mean age in the 2 groups was 39.30 10.85 and 39.82 10.92
years, respectively. The mean follow-up duration was
128.08 83.54 months overall and 130.84 87.16 months for
participants without AR. The mean eGFR values for all partici-
ation, LRD¼ living related donor, LURD¼ living unrelated donor,pants at 1 year afterKTas calculated by theCKD-EPI andMDRD
study equations were 66.54 19.85 and 59.64 17.51mL/min/
1.73m2, respectively. In participantswithoutAR, themean eGFR
www.md-journal.com | 3
FIGURE 2. Comparison between eGFR values calculated by the CKD-EPI andMDRD equations. Scatter plots of eGFR values calculated by
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at 1 year afterKTwere 69.24 18.16 and61.99 15.98mL/min/
1.73m2, respectively. The mean number of ARs per patient
during the first year after KT and the number of participants
experiencing AR over the entire follow-up period was
0.43 0.65 and 873, respectively (Table 1).
A scatter plot of eGFR values as calculated using the 2
equations indicated greater discrepancy between the 2 equations
at higher eGFR values in all participants (Figure 2A). The
Bland–Altman analysis performed to test the agreement
between eGFR as calculated using the 2 equations revealed a
mean difference between the 2 eGFR values of 6.8 overall,
suggesting that the MDRD study equation underestimated
eGFR compared to the CKD-EPI equation. Mean differences
between the 2 eGFR values increased as eGFR values increased
in all participants (beta (SE)¼0.1257 (0.0023), P< 0.0001)
(Figure 2B). Similar results were observed in the Bland–Alt-
man plot analysis of participants without an AR episode (beta
(SE)¼0.1286 (0.0032), P< 0.0001) (Figure 2C).
Cohen weighted kappa statistics showed that the agree-
ment of CKD stages based on eGFR as calculated by the 2
equations was reliable in the overall patient population and in
participants without AR (k¼ 0.7053 in the overall patient
the CKD-EPI and MDRD equations (A). Bland–Altman plots of e
participants (B) and participants without AR (C). AR¼ acute reject
eGFR¼ estimated glomerular filtration rate, MDRD¼Modificationpopulation, P< 0.0001; k¼ 0.6503 in participants without
AR, P< 0.0001). However, the CKD stages classified by the
MDRD study equation were all in lower eGFR categories than
4 | www.md-journal.comwere those classified by the CKD-EPI equation both in the
overall patient population and in participants without AR
(Figure 3). With the CKD stages assigned using the MDRD
study equation as reference, CKD stages were reclassified in
29.8% of all participants on using the CKD-EPI equation. Most
of the reclassifications were in participants classified as having
stage 3a CKD according to the MDRD study equation both in
the overall patient population and in participants without AR.
Of the 1285 participants classified as having stage 2 CKD
according to the MDRD study equation, 18.1% (n¼ 233) were
reclassified as having stage 1 CKD based on the CKD-EPI
equation, and 44.3% (n¼ 461) of the 1041 participants classi-
fied as having stage 3a CKD according to the MDRD study
equation were reclassified as having stage 2 CKD based on the
CKD-EPI equation. In participants classified as having stage 3b
CKD according to the MDRD study equation, upward reclas-
sification to stage 3a CKD based on the CKD-EPI was noted in
39.7% of participants (n¼ 182/457). Of the 1966 participants
without AR, the CKD stage was reclassified in 30.6% of all
participants on using the CKD-EPI equation; CKD was reclas-
sified in 18.4% (n¼ 167) of stage 1 patients, 46.0% (n¼ 325) of
stage 2 patients, 43.7% (n¼ 100) of stage 3a patients, and
45.8% (n¼ 11) of stage 3b patients (Figure 3).
R values calculated by the CKD-EPI and MDRD equations in all
, CKD-EPI¼Chronic Kidney Disease Epidemiology Collaboration,
Diet in Renal Disease.Next, we performed Pearson and Spearman correlation
analyses to investigate whether CKD stages based on the 2
equations were associated with graft failure in the overall
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. Status of reclassification of the CKD stage as determined by the CKD-EPI and MDRD equations in all participants (A) and in
participants without acute rejection (AR) (B). Red type indicatesmovement to a higher eGFR category. Data are represented as the number
ki
Medicine  Volume 95, Number 7, February 2016 Predicting Long-Term Kidney Graft Survivalpatient population or in thosewithout AR. Pearson and Spearman
correlation coefficients indicated that theCKD stages determined
using the CKD-EPI equation were significantly correlated with
the overall graft-failure percentage, while the CKD stage deter-
mined using the MDRD study equation was not significantly
correlated in the overall patient population (Pearson coefficient:
r¼ 0.9019, P¼ 0.01 vs r¼ 0.8044, P¼ 0.05; Spearman coeffi-
(percentage) of participants in each CKD stage. CKD¼ chronic
Collaboration, MDRD¼Modification of Diet in Renal Disease.cient: r¼ 0.8286, P¼ 0.04 vs r¼ 0.6571, P¼ 0.2) (Figure 4A).
Results for participants without AR were similar to those for the
overall patient population (Pearson coefficient: r¼ 0.8677,
FIGURE 4. Prediction of graft failure using Pearson and Spearman
between the risk of graft failure and CKD stages determined by theMD
without acute rejection (AR) (B). CKD¼ chronic kidney disease, C
MDRD¼Modification of Diet in Renal Disease.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.P¼ 0.02, vs r¼ 0.7949, P¼ 0.06; Spearman coefficient:
r¼ 0.9427, P¼ 0.002 vs r¼ 0.6571, P¼ 0.2) (Figure 4B).
Kaplan–Meier curves showed that the median graft-failure
time was 254 months for CKD stage 1 as classified by the
MDRD study equation; the median graft failure times for stages
2 and 3a as classified by the MDRD study equation were not
reached during the follow-up period (Figure 5A). By contrast,
dney disease, CKD-EPI¼Chronic Kidney Disease Epidemiologythe median graft failure time for stages 1 and 2 as classified by
the CKD-EPI equation were not reached, and the median graft-
failure time was shorter at higher stages (Figure 5B).
correlation analyses. Pearson and Spearman correlation analyses
RD and CKD-EPI equations in all participants (A) and in participants
KD-EPI¼Chronic Kidney Disease Epidemiology Collaboration,
www.md-journal.com | 5
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Choi et al Medicine  Volume 95, Number 7, February 2016In Univariate Cox regression analysis, male sex, AR, and a
higher CKD stages as classified by either equation were signifi-
FIGURE 5. Kaplan–Meier curve for median time of graft survival ac
and CKD-EPI (B). Colored lines indicate CKD stages (red: stage 1, or
purple: stage 5). CKD¼ chronic kidney disease, CKD-EPI¼Chronic
Diet in Renal Disease.cantly associated with a higher graft-failure risk, while stage
reclassification was associated with a lower graft-failure risk
(Table 2). Multivariable Cox regression analysis for graft failure
TABLE 2. Univariate Cox Regression for Graft Failure
Variables
All Participants (n¼ 3040)
HR (95% CI)
Age, y 0.996 (0.989–1.002)
Sex
Female 1 (Ref)
Male 1.310 (1.126–1.524) <
BMI at KT, kg/m2 1.007 (0.967–1.048)
Dialysis duration, mo 1.000 (0.997–1.002)
AR
No 1 (Ref)
Yes 3.409 (2.911–3.992) <
Stage reclassification
No 1 (Ref)
Yes 0.798 (0.685–0.930)
MDRD eGFR category
Stage 1 1 (Ref)
Stage 2 0.720 (0.534–0.971)
Stage 3a 0.916 (0.677–1.241)
Stage 3b 1.534 (1.112–2.115)
Stage 4 5.785 (3.956–8.459) <
Stage 5 22.868 (12.535–41.720) <
CKD-EPI eGFR category
Stage 1 1 (Ref)
Stage 2 1.031 (0.828–1.284)
Stage 3a 1.361 (1.072–1.728)
Stage 3b 2.840 (2.170–3.717) <
Stage 4 8.874 (6.267–12.565) <
Stage 5 52.282 (28.795–94.925) <
AR¼ acute rejection, BMI¼ body mass index, CI¼ confidence interva
HR¼ hazard ratio, KT¼ kidney transplantation, MDRD¼Modification of
6 | www.md-journal.comwas adjusted for age, sex, AR, stage reclassification, and CKD
stage as classified by either equation. Stage reclassification was
ding to CKD stages determined by each eGFR equation: MDRD (A)
e: stage 2, yellow: stage 3a, green: stage 3b, blue dotted: stage 4,
ney Disease Epidemiology Collaboration, MDRD¼Modification ofassociated with a significantly decreased graft-failure risk after
adjusting for age, sex, AR, and CKD stage as classified by the
MDRDstudy equation. Interestingly, stage reclassificationwas not
Participants Without AR (n¼ 1966)
P HR (95% CI) P
0.19 0.984 (0.972–0.996) 0.01
1 (Ref)
0.001 1.533 (1.154–2.037) 0.003
0.73 1.035 (0.974–1.100) 0.26
0.81 0.998 (0.993–1.003) 0.38
— —
0.001 — —
1 (Ref)
0.004 0.880 (0.673–1.150) 0.35
1 (Ref)
0.03 0.689 (0.417–1.139) 0.15
0.57 1.135 (0.686–1.879) 0.62
0.009 1.675 (0.942–2.975) 0.08
0.001 12.089 (5.184–28.191) <0.001
0.001 146.928 (18.196–1186.378) <0.001
1 (Ref)
0.78 1.207 (0.826–1.763) 0.33
0.01 1.813 (1.198–2.744) 0.005
0.001 3.623 (2.098–6.256) <0.001
0.001 28.650 (11.867–69.170) <0.001
0.001 221.576 (28.093–1747.605) <0.001
l, CKD-EPI¼Chronic Kidney Disease Epidemiology Collaboration,
Diet in Renal Disease.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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associated with decreased graft survival after adjustment for age,
Choi et alsex, AR, and CKD stage as classified by the CKD-EPI equation as
opposed to CKD stage as classified by the MDRD study equation.
Similar results were observed in participantswithoutAR (Table 3).
DISCUSSION
Our data of 3040 KT recipients over a 10-year follow-up
period showed that eGFR was reclassified to a higher eGFR
category based on the CKD-EPI equation as compared to the
MDRD study equation classification in almost one-third of
participants. This retrospective cohort study also demonstrated
that stage reclassification was associated with a significantly
lower risk of graft failure.
Several methods for GFR measurement have been used
since the use of urinary inulin clearance for GFR measurement
was developed, but these direct measurements are only avail-
able in major medical centers. Therefore, GFR estimation using
endogenous filtration markers rather than mGFR is commonly
employed to evaluate CKD.28 However, Shaffi et al22 reported a
wide range of bias and accuracy across studies, with both the
overestimation and underestimation of mGFR using creatinine-
based estimation equations because of differences in race, the
reference standard used for GFR measurement, and creatinine
assay calibration. A recent study reported that the CKD-EPI
creatinine equation was not a better predictor of GFR than the
MDRD study equation in a large cohort of transplant patients in
whom GFR was evaluated by either urinary inulin clearance or
plasma 51Cr-EDTA clearance.6 Instead of comparing the per-
formance of these 2 equations to approximate the mGFR, the
present study validated creatinine-based GFR estimation
equations using long-term clinical outcomes in KT patients
in a single center. In this study, eGFR determined by the CKD-
EPI equation at 1 year post-KT had good predictive power for
graft survival in a large cohort of KT patients over a 10-year
follow-up period. In clinical practice, a simple tool to assess
renal function may be more important for predicting graft
survival and the risk of mortality in KT patients than mGFR,
which is difficult to determine repeatedly in KT patients.
Based on data from patients with CKD, several limitations
of the MDRD study equation have been reported, including a
lack of precision and an underestimation of GFR, especially in
patients with early-stage CKD.25,29 In a recent meta-analysis of
data from 1.1 million adults, eGFR was reclassified to a higher
category in approximately one-fourth of participants on using
the CKD-EPI equation compared to the stage determined using
the MDRD study equation. Interestingly, participants in whom
eGFR was reclassified upward had a lower risk of mortality
and ESRD than those in whom eGFR was not reclassified, after
adjusting for age, sex, race/ethnicity, and other potential con-
founders.24 Our study also demonstrated that participants in
whom eGFR was reclassified upward based on the CKD-EPI
equation had a lower graft-failure risk after adjusting for age,
sex, AR status, and CKD stage. Notably, all KT patients
in whom eGFR was reclassified showed a move to a higher
eGFR category based on the CKD-EPI equation compared
with the MDRD study equation classification. Additionally,
a Bland–Altman plot analysis of our results showed that
eGFR was significantly underestimated by the MDRD study
equation at all CKD stages compared to the CKD-EPI equation
classification.In a previous report regarding CKD progression in CKD
patients with type 2 diabetes, the CKD-EPI equation facilitated
more accurate stratifications in earlier-stage CKD than did the
8 | www.md-journal.comMDRD study equation.25 Our Kaplan–Meier analysis indicated
that CKD stage stratification by the CKD-EPI equation was
more accurate in predicting graft failure than was stratification
by the MDRD study equation and revealed poorer graft survival
in stage 1 CKD patients than in stage 2 and 3a CKD patients.
Multivariable Cox regression analysis also showed that CKD
stages as classified by the CKD-EPI equation were more
accurately associated with increased hazard ratios (HRs) for
graft failure than were those classified by the MDRD study
equation.
Several studies have shown that a higher eGFR was
paradoxically associated with increased mortality with respect
to muscle wasting secondary to poor health.24,30 A recent meta-
analysis reported that this riskwas not evident in the unadjusted
analysis but was evident after age adjustment, suggesting that
the CKD-EPI equation could not fully overcome this limitation
inherent to creatinine-based eGFR equations.24 Moreover,
GFR prediction equations using serum creatinine have been
reported to overestimate mGFR in KT patients on and off
steroid regimens.31 Kasiske et al reported that relatively lower
serum creatinine levels in some patients were due to decreased
muscle mass and that the comorbidity giving rise to decreased
muscle mass may have been associated with a higher risk of
graft failure. The small number of KT patients with stage 1
CKD at 12 months after transplantation had a higher rate of
graft failure due to increased mortality.32 By contrast, in the
present study, higher CKD stages as classified by the CKD-EPI
equation were significantly associated with greater HRs for
graft failure (HR: 1.1 for stage 2 and 1.441 for stage 3a based on
the CKD-EPI equation), whereas stage 2 CKD as classified by
the MDRD study equation had lower HRs for graft failure (HR
for graft failure: 0.796 for stage 2; 1.179 for stage 3a based on
the MDRD study equation) in both Univariate and multi-
variable Cox analyses, after adjusting for age, sex, AR, and
stage reclassification. Taken together, these results suggest that
CKD stages determined by the CKD-EPI equation might more
accurately predict graft survival in patients with KT than might
those determined using the MDRD equation, especially in the
earlier stages. Moreover, the multivariable Cox analysis
suggested that stage reclassification was associated with a
lower risk of graft failure after adjustment for CKD stages
as classified by the MDRD study equation, while any signifi-
cant association with a decreased risk of graft failure was lost
after adjustment for CKD stages classified by the CKD-
EPI equation.
In addition to its retrospective nature, there are several
limitations to this study. First, we did not evaluate the accuracy
of the 2 equations for estimating GFR in KT patients by
comparing the eGFR values with mGFR values using inulin
or isotopes. Second, although the CKD-EPI equation has stron-
ger clinical implications than does the MDRD study equation
for the earlier stages of CKD, it still involves the inherent
limitations of the use of serum creatinine, which is dependent on
muscle mass, creatinine generation, and tubular secretion. A
large overestimation was observed in our transplant recipients at
eGFR levels90mL/min/1.73m2 and this can be considered an
artifact. This overestimation was attributable to low serum
creatinine levels caused by muscle wasting with comorbid
conditions in transplant recipients. Finally, this study comprised
only Korean KT patients, preventing our results from being
generalized to other ethnic populations.
Medicine  Volume 95, Number 7, February 2016In summary, we found that eGFR was underestimated by
the MDRD equation compared to eGFR determined by the
CKD-EPI equation in KT patients. Both Univariate and
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
multivariable Cox regression analyses indicated that higher
CKD stages as determined by the CKD-EPI equation were
significantly associated with a greater risk of graft failure,
whereas a stage 2 classification based on the MDRD study
equation was associated with a lower risk of graft failure. Stage
reclassification was associated with a significantly decreased
risk of graft failure, after adjusting for age, sex, AR, and CKD
stage as classified by the MDRD equation but not the CKD-EPI
equation in multivariable Cox regression analysis. Our results
suggest that eGFR calculated by the CKD-EPI equation has a
Medicine  Volume 95, Number 7, February 2016stronger predictive power for long-term kidney graft survival in
transplantation settings than does that determined by theMDRD
study equation.
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